Methods and compositions for the amplification of mutations in the diagnosis of cystic fibrosis
First Claim
Patent Images
1. A substantially purified nucleic acid sample comprising one or more nucleic acids having sequences selected from the group consisting of:
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides nucleic acid primers for amplifying DNA sequences of normal and mutant cystic fibrosis (CF) genes. These primers enable the construction of assays that use the amplified CF genes to detect of the presence of normal or mutant CF sequence, thereby enabling the detection of the genotype of cystic fibrosis in a biological sample. Various pairs of primers suitable for amplifying different CFTR gene segments are provided which are suitable for use in a multiplex amplification format.
49 Citations
27 Claims
- 1. A substantially purified nucleic acid sample comprising one or more nucleic acids having sequences selected from the group consisting of:
-
4. A method of amplifying a nucleic acid sequence, comprising,
contacting a nucleic acid containing sample with reagents suitable for nucleic acid amplification including one or more pairs of primers flanking one or more predetermined nucleic acid sequences that are correlated with cystic fibrosis, and amplifying said one or more predetermined nucleic acid sequences, if present, wherein said primers are one or more pairs of nucleic acids selected from the group consisting of: 5′
-GCGGTCCCAAAAGGGTCAGTTGTAGGAAGTCACCAAAG-3′
,(SEQ ID NO;
3)5′
-GCGGTCCCAAAAGGGTCAGTCGATACAGAATATATGTGCC-3′
,(SEQ ID NO;
4)5′
-GCGGTCCCAAAAGGGTCAGTGAATCATTCAGTGGGTATAAGCAG-3′
,(SEQ ID NO;
5)5′
-GCGGTCCCAAAAGGGTCAGTCTTCAATGCACCTCCTCCC-3′
,(SEQ ID NO;
6)5′
-GCGGTCCCAAAAGGGTCAGTAGATACTTCAATAGCTCAGCC-3′
,(SEQ ID NO;
7)5′
-GCGGTCCCAAAAGGGTCAGTGGTACATTACCTGTATTTTGTTT-3′
,(SEQ ID NO;
8)5′
-GCGGTCCCAAAAGGGTCAGTGTGAATCGATGTGGTGACCA-3′
,(SEQ ID NO;
9)5′
-GCGGTCCCAAAAGGGTCAGTCTGGTTTAGCATGAGGCGGT-3′
,(SEQ ID NO;
10)5′
-GCGGTCCCAAAAGGGTCAGTTTGGTTGTGCTGTGGCTCCT-3′
,(SEQ ID NO;
11)5′
-GCGGTCCCAAAAGGGTCAGTACAATACATACAAACATAGTGG-3′
,(SEQ ID NO;
12)5′
-GCGGTCCCAAAAGGGTCAGTGAAAGTATTTATTTTTTCTGGAAC-3′
,(SEQ ID NO;
13)5′
-GCGGTCCCAAAAGGGTCAGTGTGTGTAGAATGATGTCAGCTAT-3′
,(SEQ ID NO;
14)5′
-GCGGTCCCAAAAGGGTCAGTCAGATTGAGCATACTAAAAGTG-3′
,(SEQ ID NO;
15)5′
-GCGGTCCCAAAAGGGTCAGTTACATGAATGACATTTACAGCA-3′
,(SEQ ID NO;
16)5′
-GCGGTCCCAAAAGGGTCAGTAAGAACTGGATCAGGGAAGA-3′
,(SEQ ID NO;
17)5′
-GCGGTCCCAAAAGGGTCAGTTCCTTTTGCTCACCTGTGGT-3′
,(SEQ ID NO;
18)5′
-GCGGTCCCAAAAGGGTCAGTGGTCCCACTTTTTATTCTTTTGC-3′
,(SEQ ID NO;
19)5′
-GCGGTCCCAAAAGGGTCAGTTGGTTTCTTAGTGTTTGGAGTTG-3′
,(SEQ ID NO;
20)5′
-GCGGTCCCAAAAGGGTCAGTTGGATCATGGGCCATGTGC-3′
,(SEQ ID NO;
21)5′
-GCGGTCCCAAAAGGGTCAGTACTACCTTGCCTGCTCCAGTGG-3′
,(SEQ ID NO;
22)5′
-GCGGTCCCAAAAGGGTCAGTAGGTAGCAGCTATTTTTATGG-3′
,(SEQ ID NO;
23)5′
-GCGGTCCCAAAAGGGTCAGTTAAGGGAGTCTTTTGCACAA-3′
,(SEQ ID NO;
24)5′
-GCGGTCCCAAAAGGGTCAGTGCAATTTTGGATGACCTTC-3′
,(SEQ ID NO;
25)5′
-GCGGTCCCAAAAGGGTCAGTTAGACAGGACTTCAACCCTC-3′
,(SEQ ID NO;
26)5′
-GCGGTCCCAAAAGGGTCAGTGGTGATTATGGGAGAACTGG-3′
,(SEQ ID NO;
27)5′
-GCGGTCCCAAAAGGGTCAGTATGCTTTGATGACGCTTC-3′
,(SEQ ID NO;
28)5′
-GCGGTCCCAAAAGGGTCAGTTTCATTGAAAAGCCCGAC-3′
,(SEQ ID NO;
29)5′
-GCGGTCCCAAAAGGGTCAGTCACCTTCTGTGTATTTTGCTG-3′
,(SEQ ID NO;
30)5′
-GCGGTCCCAAAAGGGTCAGTAAGTATTGGACAACTTGTTAGTCTC-3′
,(SEQ ID NO;
31)5′
-GCGGTCCCAAAAGGGTCAGTCGCCTTTCCAGTTGTATAATTT-3′
.(SEQ ID NO;
32)- View Dependent Claims (5, 6, 7, 8, 9)
-
10. A method of determining the presence or absence of one or nucleic acid sequences correlated with cystic fibrosis in a nucleic acid containing sample, comprising:
-
contacting said sample with reagents suitable for nucleic acid amplification including one or more pairs of nucleic acid primers flanking one or more predetermined nucleic acid sequences that are correlated with cystic fibrosis, amplifying said predetermined nucleic acid sequence(s), if present, to provide an amplified sample; and
identifying the presence or absence of said one or more predetermined sequences in said amplified sample, whereby the presence or absence of said one or more nucleic acid sequences correlated with cystic fibrosis is determined;
wherein said pairs of nucleic acid primers are selected from the group consisting of;
5′
-GCGGTCCCAAAAGGGTCAGTTGTAGGAAGTCACCAAAG-3′(SEQ ID NO;
3)and 5′
-GCGGTCCCAAAAGGGTCAGTCGATACAGAATATATGTGCC-3′
,(SEQ ID NO;
4)5′
-GCGGTCCCAAAAGGGTCAGTGAATCATTCAGTGGGTATAAGCAG-3′(SEQ ID NO;
5)and 5′
-GCGGTCCCAAAAGGGTCAGTCTTCAATGCACCTCCTCCC-3′
,(SEQ ID NO;
6)5′
-GCGGTCCCAAAAGGGTCAGTAGATACTTCAATAGCTCAGCC-3′(SEQ ID NO;
7)and 5′
-GCGGTCCCAAAAGGGTCAGTGGTACATTACCTGTATTTTGTTT-3′
,(SEQ ID NO;
8)5′
-GCGGTCCCAAAAGGGTCAGTGTGAATCGATGTGGTGACCA-3′(SEQ ID NO;
9)and 5′
-GCGGTCCCAAAAGGGTCAGTCTGGTTTAGCATGAGGCGGT-3′
,(SEQ ID NO;
10)5′
-GCGGTCCCAAAAGGGTCAGTTTGGTTGTGCTGTGGCTCCT-3′(SEQ ID NO;
11)and 5′
-GCGGTCCCAAAAGGGTCAGTACAATACATACAAACATAGTGG-3′
,(SEQ ID NO;
12)5′
-GCGGTCCCAAAAGGGTCAGTGAAAGTATTTATTTTTTCTGGAAC-3′(SEQ ID NO;
13)and 5′
-GCGGTCCCAAAAGGGTCAGTGTGTGTAGAATGATGTCAGCTAT-3′
,(SEQ ID NO;
14)5′
-GCGGTCCCAAAAGGGTCAGTCAGATTGAGCATACTAAAAGTG-3′(SEQ ID NO;
15)and 5′
-GCGGTCCCAAAAGGGTCAGTTACATGAATGACATTTACAGCA-3′
,(SEQ ID NO;
16)5′
-GCGGTCCCAAAAGGGTCAGTAAGAACTGGATCAGGGAAGA-3′(SEQ ID NO;
17)and 5′
-GCGGTCCCAAAAGGGTCAGTTCCTTTTGCTCACCTGTGGT-3′
,(SEQ ID NO;
18)5′
-GCGGTCCCAAAAGGGTCAGTGGTCCCACTTTTTATTCTTTTGC-3′(SEQ ID NO;
19)and 5′
-GCGGTCCCAAAAGGGTCAGTTGGTTTCTTAGTGTTTGGAGTTG-3′
,(SEQ ID NO;
20)5′
-GCGGTCCCAAAAGGGTCAGTTGGATCATGGGCCATGTGC-3′(SEQ ID NO;
21)and 5′
-GCGGTCCCAAAAGGGTCAGTACTACCTTGCCTGCTCCAGTGG-3′
,(SEQ ID NO;
22)5′
-GCGGTCCCAAAAGGGTCAGTAGGTAGCAGCTATTTTTATGG-3′(SEQ ID NO;
23)and 5′
-GCGGTCCCAAAAGGGTCAGTTAAGGGAGTCTTTTGCACAA-3′
,(SEQ ID NO;
24)5′
-GCGGTCCCAAAAGGGTCAGTGCAATTTTGGATGACCTTC-3′(SEQ ID NO;
25)and 5′
-GCGGTCCCAAAAGGGTCAGTTAGACAGGACTTCAACCCTC-3′
,(SEQ ID NO;
26)5′
-GCGGTCCCAAAAGGGTCAGTGGTGATTATGGGAGAACTGG-3′(SEQ ID NO;
27)and 5′
-GCGGTCCCAAAAGGGTCAGTATGCTTTGATGACGCTTC-3′
,(SEQ ID NO;
28)5′
-GCGGTCCCAAAAGGGTCAGTTTCATTGAAAAGCCCGAC-3′(SEQ ID NO;
29)and 5′
-GCGGTCCCAAAAGGGTCAGTCACCTTCTGTGTATTTTGCTG-3′
,(SEQ ID NO;
30)and 5′
-GCGGTCCCAAAAGGGTCAGTAAGTATTGGACAACTTGTTAGTCTC-3′(SEQ ID NO;
31)and 5′
-GCGGTCCCAAAAGGGTCAGTCGCCTTTCCAGTTGTATAATTT-3′
.(SEQ ID NO;
32) - View Dependent Claims (11, 12, 13, 14, 15, 16)
-
-
17. A method of determining whether a subject has a genotype containing one or more nucleotide sequences correlated with cystic fibrosis, comprising:
-
obtaining a sample of nucleic acid from the subject;
contacting said sample with reagents suitable for nucleic acid amplification including one or more pairs of nucleic acid primers flanking one or more predetermined nucleic acid sequences that are correlated with cystic fibrosis, amplifying said predetermined nucleic acid sequence(s), if present, to provide an amplified sample; and
identifying the presence of said one or more nucleic acid sequences correlated with cystic fibrosis nucleic, whereby the presence of one or more nucleic acid sequences correlated with cystic fibrosis in the genotype of the subject is determined;
wherein said pairs of nucleic acid primers are selected from the group consisting of;
5′
-GCGGTCCCAAAAGGGTCAGTTGTAGGAAGTCACCAAAG-3′(SEQ ID NO;
3)and 5′
-GCGGTCCCAAAAGGGTCAGTCGATACAGAATATATGTGCC-3′
,(SEQ ID NO;
4)5′
-GCGGTCCCAAAAGGGTCAGTGAATCATTCAGTGGGTATAAGCAG-3′(SEQ ID NO;
5)and 5′
-GCGGTCCCAAAAGGGTCAGTCTTCAATGCACCTCCTCCC-3′
,(SEQ ID NO;
6)5′
-GCGGTCCCAAAAGGGTCAGTAGATACTTCAATAGCTCAGCC-3′(SEQ ID NO;
7)and 5′
-GCGGTCCCAAAAGGGTCAGTGGTACATTACCTGTATTTTGTTT-3′
,(SEQ ID NO;
8)5′
-GCGGTCCCAAAAGGGTCAGTGTGAATCGATGTGGTGACCA-3′(SEQ ID NO;
9)and 5′
-GCGGTCCCAAAAGGGTCAGTCTGGTTTAGCATGAGGCGGT-3′
,(SEQ ID NO;
10)5′
-GCGGTCCCAAAAGGGTCAGTTTGGTTGTGCTGTGGCTCCT-3′(SEQ ID NO;
11)and 5′
-GCGGTCCCAAAAGGGTCAGTACAATACATACAAACATAGTGG-3′
,(SEQ ID NO;
12)5′
-GCGGTCCCAAAAGGGTCAGTGAAAGTATTTATTTTTTCTGGAAC-3′(SEQ ID NO;
13)and 5′
-GCGGTCCCAAAAGGGTCAGTGTGTGTAGAATGATGTCAGCTAT-3′
,(SEQ ID NO;
14)5′
-GCGGTCCCAAAAGGGTCAGTCAGATTGAGCATACTAAAAGTG-3′(SEQ ID NO;
15)and 5′
-GCGGTCCCAAAAGGGTCAGTTACATGAATGACATTTACAGCA-3′
,(SEQ ID NO;
16)5′
-GCGGTCCCAAAAGGGTCAGTAAGAACTGGATCAGGGAAGA-3′(SEQ ID NO;
17)and 5′
-GCGGTCCCAAAAGGGTCAGTTCCTTTTGCTCACCTGTGGT-3′
,(SEQ ID NO;
18)5′
-GCGGTCCCAAAAGGGTCAGTGGTCCCACTTTTTATTCTTTTGC-3′(SEQ ID NO;
19)and 5′
-GCGGTCCCAAAAGGGTCAGTTGGTTTCTTAGTGTTTGGAGTTG-3′
,(SEQ ID NO;
20)5′
-GCGGTCCCAAAAGGGTCAGTTGGATCATGGGCCATGTGC-3′(SEQ ID NO;
21)and 5′
-GCGGTCCCAAAAGGGTCAGTACTACCTTGCCTGCTCCAGTGG-3′
,(SEQ ID NO;
22)5′
-GCGGTCCCAAAAGGGTCAGTAGGTAGCAGCTATTTTTATGG-3′(SEQ ID NO;
23)and 5′
-GCGGTCCCAAAAGGGTCAGTTAAGGGAGTCTTTTGCACAA-3′
,(SEQ ID NO;
24)5′
-GCGGTCCCAAAAGGGTCAGTGCAATTTTGGATGACCTTC-3′(SEQ ID NO;
25)and 5′
-GCGGTCCCAAAAGGGTCAGTTAGACAGGACTTCAACCCTC-3′
,(SEQ ID NO;
26)5′
-GCGGTCCCAAAAGGGTCAGTGGTGATTATGGGAGAACTGG-3′(SEQ ID NO;
27)and 5′
-GCGGTCCCAAAAGGGTCAGTATGCTTTGATGACGCTTC-3′
,(SEQ ID NO;
28)5′
-GCGGTCCCAAAAGGGTCAGTTTCATTGAAAAGCCCGAC-3′(SEQ ID NO;
29)and 5′
-GCGGTCCCAAAAGGGTCAGTCACCTTCTGTGTATTTTGCTG-3′
,(SEQ ID NO;
30)and 5′
-GCGGTCCCAAAAGGGTCAGTAAGTATTGGACAACTTGTTAGTCTC-3′(SEQ ID NO;
31)and 5′
-GCGGTCCCAAAAGGGTCAGTCGCCTTTCCAGTTGTATAATTT-3′
.(SEQ ID NO;
32) - View Dependent Claims (18, 19, 20, 21, 22, 23)
-
- 24. A kit for amplifying sequences of the cystic fibrosis CTFR gene comprising one or more pairs of nucleic acid primers selected from the group consisting of:
Specification